A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa.
Tirzepatide isn’t just grabbing headlines for its metabolic effects. Now, a new case report out of Japan puts a fresh spotlight on what happens when this research peptide gets pushed far past clinical norms. Researchers detailed the story of a 53-year-old woman with type 2 diabetes and bulimia nervosa who self-injected tirzepatide at escalating doses—7.5 mg, 10 mg, then 15 mg—over three days. That’s way above the intended research protocol. The result: a prolonged paralytic ileus, where her gut basically hit pause for weeks.
Intern Med
by Asada K, Tsujimoto Y, Hoshino Y et al.
“A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa. Asada K(1), Tsujimoto Y(1), Hoshino Y(1), Tomiki M(1), Sekiguchi K(1), Yamashiro K(1), Nishimura R(1). Author information: (1)Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Japan. We report the case of a 53-year-old woman with type 2 diabetes and bulimia nervosa who developed prolonged paralytic ileus after self-injecting tirzepatide 7.5 mg, 10 mg, and 15 mg on three consecutive days. Tirzepatide had been prescribed for diabetes treatment. However, the excessive self-administration resulted in paralytic ileus. No mechanical obstruction was found, and the condition resolved after three weeks of conservative therapy, including gastrointestinal decompression and prokinetic agents. Because tirzepatide has a long half-life, an overdose may cause the persistent suppression of intestinal motility. Misunderstanding about drug effects may lead to an overdose, thus requiring careful instruction and medication management.”
No mechanical blockage. No surgery needed. Just a frustrating, stubborn shutdown of intestinal movement. The team used conservative measures—GI decompression, prokinetic agents—and eventually, her system rebooted after three weeks. The culprit? Tirzepatide’s long half-life. When you stack doses, the gut-slowing effects can linger far longer than researchers might expect.
Key takeaway:
Tirzepatide research should factor in the peptide’s long duration of action
Overlapping doses can lead to pronounced, persistent gastrointestinal effects
Conservative management can resolve the issue, but patience is required
This case doesn’t tarnish the reputation of tirzepatide. If anything, it highlights just how potent these research compounds can be—especially when used outside standard parameters. It’s a reminder for the research community to respect the kinetics of powerful peptides and double-check protocols when stacking or escalating doses.
Curious about mechanisms, structure, or ongoing research? Check out the main tirzepatide page for more details. For anyone sourcing research peptides, our vendor directory connects you to reliable suppliers.
Big picture: tirzepatide continues to show promise, but researchers should always pay attention to its unique pharmacology when designing studies.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.